盐诱导激酶抑制在体内抑制急性髓系白血病进展
本研究评估了工具化合物YKL-05-099抑制SIK3对MEF2C高表达急性髓系白血病(AML)的作用。在体外,YKL-05-099通过抑制SIK3激酶活性,改变HDAC4磷酸化与核定位,抑制MEF2C功能,导致细胞周期阻滞和凋亡。在两种MLL-AF9 AML小鼠模型中,YKL-05-099在耐受剂量下延缓疾病进展并延长生存,验证SIK3为MEF2C依赖型AML的治疗靶点。
要点
- SIK3通过磷酸化HDAC4维持MEF2C功能,支持MEF2C高表达AML生长。
- YKL-05-099靶向抑制SIK3,在MEF2C表达AML细胞中诱导周期阻滞和凋亡。
- 在MLL-AF9 AML小鼠模型中,YKL-05-099耐受良好并延长生存。
核心结论
- 抑制SIK3可抑制MEF2C功能并延缓MEF2C依赖型AML的疾病进展。
- SIK3是MEF2C高表达AML的潜在治疗靶点,支持开发类药性SIK3抑制剂。
研究设计与样本
- 研究使用工具化合物YKL-05-099以及遗传靶向SIK3或MEF2C,在体外细胞和体内动物模型中评估其对AML的作用。
- 体内实验采用2种不同的MLL-AF9 AML小鼠模型,以耐受剂量给予YKL-05-099治疗。
主要发现
- 遗传靶向SIK3或MEF2C在体外和体内选择性抑制转化造血细胞的生长。
- YKL-05-099在MEF2C表达的AML细胞系中引起细胞周期阻滞和凋亡。
- YKL-05-099快速改变HDAC4磷酸化状态和核定位,从而抑制MEF2C功能。
- 利用SIK3 gatekeeper等位基因证实YKL-05-099的抗增殖作用通过靶向抑制SIK3激酶活性实现。
- 在2种MLL-AF9 AML小鼠模型中,YKL-05-099在耐受剂量下延缓疾病进展并延长动物生存。
临床怎么用
- 对于MEF2C高表达的AML,可考虑将SIK3抑制作为潜在治疗策略,但尚需临床研究验证。
- YKL-05-099作为工具化合物,可用于临床前研究评估SIK3抑制剂类药物的疗效与安全性。
局限性
- 研究仅使用工具化合物YKL-05-099,尚未评估类药性SIK3抑制剂的临床前和临床效果。
- 体内实验仅采用MLL-AF9 AML小鼠模型,结果外推到其他AML亚型需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lineage-defining transcription factors (TFs) are compelling targets for leukemia therapy, yet they are among the most challenging proteins to modulate directly with small molecules. We previously used CRISPR screening to identify a salt-inducible kinase 3 (SIK3) requirement for the growth of acute myeloid leukemia (AML) cell lines that overexpress the lineage TF myocyte enhancer factor (MEF2C). In this context, SIK3 maintains MEF2C function by directly phosphorylating histone deacetylase 4 (HDAC4), a repressive cofactor of MEF2C. In this study, we evaluated whether inhibition of SIK3 with the tool compound YKL-05-099 can suppress MEF2C function and attenuate disease progression in animal models of AML. Genetic targeting of SIK3 or MEF2C selectively suppressed the growth of transformed hematopoietic cells under in vitro and in vivo conditions. Similar phenotypes were obtained when cells were exposed to YKL-05-099, which caused cell-cycle arrest and apoptosis in MEF2C-expressing AML cell lines. An epigenomic analysis revealed that YKL-05-099 rapidly suppressed MEF2C function by altering the phosphorylation state and nuclear localization of HDAC4. Using a gatekeeper allele of SIK3, we found that the antiproliferative effects of YKL-05-099 occurred through on-target inhibition of SIK3 kinase activity. Based on these findings, we treated 2 different mouse models of MLL-AF9 AML with YKL-05-099, which attenuated disease progression in vivo and extended animal survival at well-tolerated doses. These findings validate SIK3 as a therapeutic target in MEF2C-addicted AML and provide a rationale for developing druglike inhibitors of SIK3 for definitive preclinical investigation and for studies in human patients.
引用
- Tarumoto Y, Lin S, Wang J, et al. Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo. Blood. 2020. PMID: 31697837. doi:10.1182/blood.2019001576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。